Detection and treatment of at-risk mental state for developing a first psychosis: Making up the balance

The Lancet Psychiatry

Volumn 2, Issue 9, 2015, Pages 825-834

  Nieman, Dorien H ^a   McGorry, Patrick D ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

AT RISK MENTAL STATE; DISEASE CLASSIFICATION; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HEALTH CARE; HEALTH CARE PLANNING; HELP SEEKING BEHAVIOR; HUMAN; MENTAL DISEASE; MENTAL HEALTH; META ANALYSIS; PERSONALIZED MEDICINE; PSYCHOSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STIGMA; TREATMENT PLANNING; COMPLICATION; MENTAL DISORDERS; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS;

HUMANS; MENTAL DISORDERS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS;

EID: 84940775524     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(15)00221-7     Document Type: Review

References (118)

1. McGorry P, van Os J Redeeming diagnosis in psychiatry: timing versus specificity. Lancet 2013, 381:343-345.
2. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006, 40:616-622.
3. Johannessen JO, Larsen TK, Joa I, et al. Pathways to care for first-episode psychosis in an early detection healthcare sector: part of the Scandinavian TIPS study. Br J Psychiatry Suppl 2005, 48:s24-s28.
4. Joa I, Johannessen JO, Auestad B, et al. The key to reducing duration of untreated first psychosis: information campaigns. Schizophr Bull 2008, 34:466-472.
5. Van Os J The dynamics of subthreshold psychopathology: implications for diagnosis and treatment. Am J Psychiatry 2013, 170:695-698.
6. McGorry PD Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. Am J Psychiatry 2007, 164:859-860.
7. McGorry PD Early clinical phenotypes, clinical staging, and strategic biomarker research: building blocks for personalized psychiatry. Biol Psychiatry 2013, 74:394-395.
8. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003, 29:703-715.
9. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull 2003, 29:633-651.
10. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996, 22:283-303.
11. Yung AR, Nelson B, Stanford C, et al. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res 2008, 105:10-17.
12. Ruhrmann S, Schultze-Lutter F, Salokangas RK, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European Prediction of Psychosis Study. Arch Gen Psychiatry 2010, 67:241-251.
13. Frances A The new crisis of confidence in psychiatric diagnosis. Ann Intern Med 2013, 159:221-222.
14. Reeves WC, Strine TW, Pratt LA, et al. Mental illness surveillance among adults in the United States. MMWR Surveill Summ 2011, 60(suppl 3):1-29. the Centers for Disease Control and Prevention (CDC).
15. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013, 310:591-608. US Burden of Disease Collaborators.
16. Insel TR Assessing the economic costs of serious mental illness. Am J Psychiatry 2008, 165:663-665.
17. Making mental health count Organisation for Economic Co-operation and Development (OECD), (accessed July 1, 2015). http://www.oecd.org/els/health-systems/Focus-on-Health-Making-Mental-Health-Count.pdf.
18. McGorry PD, Purcell R, Goldstone S, Amminger GP Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care. Curr Opin Psychiatry 2011, 24:301-306.
19. Slade T, Johnston A, Teesson M, et al. The mental health of Australians 2. Report on the 2007 National Survey of Mental Health and Wellbeing 2009, Australian Department of Health and Ageing, Canberra.
20. Werbeloff N, Drukker M, Dohrenwend BP, et al. Self-reported attenuated psychotic symptoms as forerunners of severe mental disorders later in life. Arch Gen Psychiatry 2012, 69:467-475.
21. Kaymaz N, Drukker M, Lieb R, et al. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. Psychol Med 2012, 42:2239-2253.
22. Schultze-Lutter F, Michel C, Ruhrmann S, Schimmelmann BG Prevalence and clinical significance of DSM-5-attenuated psychosis syndrome in adolescents and young adults in the general population: the Bern Epidemiological At-Risk (BEAR) study. Schizophr Bull 2014, 40:1499-1508.
23. Deacon BJ The biomedical model of mental disorder: a critical analysis of its validity, utility, and effects on psychotherapy research. Clin Psychol Rev 2013, 33:846-861.
24. The Netherlands Centraal Bureau voor de Statistiek, (accessed July 6, 2015). http://statline.cbs.nl/Statweb/.
25. Nordentoft M, Melau M, Iversen T, et al. From research to practice: how OPUS treatment was accepted and implemented throughout Denmark. Early Interv Psychiatry 2015, 9:156-162.
26. Kahn RS, Keefe RS Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 2013, 70:1107-1112.
27. Insel TR Rethinking schizophrenia. Nature 2010, 468:187-193.
28. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223. the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators.
29. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909.
30. Colton CW, Manderscheid RW Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3:A42.
31. Diagnostic and statistical manual on mental disorders, (DSM-IV) 1994, American Psychiatric Association, American Psychiatric Press, Washington, DC. 4th edition.
32. Van Beveren NJ, Hoogendijk WJ Clinical utility of serum biomarkers for major psychiatric disorders. Int Rev Neurobiol 2011, 101:351-374.
33. Borsboom D, Cramer AO Network analysis: an integrative approach to the structure of psychopathology. Annu Rev Clin Psychol 2013, 9:91-121.
34. Dalal PK, Sivakumar T Moving towards ICD-11 and DSM-V: Concept and evolution of psychiatric classification. Indian J Psychiatry 2009, 51:310-319.
35. Maj M "Psychiatric comorbidity": an artefact of current diagnostic systems?. Br J Psychiatry 2005, 186:182-184.
36. Kessler RC, Ormel J, Petukhova M, et al. Development of lifetime comorbidity in the World Health Organization world mental health surveys. Arch Gen Psychiatry 2011, 68:90-100.
37. Roca M, Gili M, Garcia-Garcia M, et al. Prevalence and comorbidity of common mental disorders in primary care. J Affect Disord 2009, 119:52-58.
38. Hickie IB, Scott J, Hermens DF, et al. Clinical classification in mental health at the cross-roads: which direction next?. BMC Med 2013, 11:125.
39. Lichtenstein P, Yip BH, Björk C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009, 373:234-239.
40. Sullivan PF, Daly MJ, O'Donovan M Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet 2012, 13:537-551.
41. Merikangas KR, Cui L, Kattan G, Carlson GA, Youngstrom EA, Angst J Mania with and without depression in a community sample of US adolescents. Arch Gen Psychiatry 2012, 69:943-951.
42. Kelleher I, Keeley H, Corcoran P, et al. Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies. Br J Psychiatry 2012, 201:26-32.
43. Lahey BB, Zald DH, Hakes JK, Krueger RF, Rathouz PJ Patterns of heterotypic continuity associated with the cross-sectional correlational structure of prevalent mental disorders in adults. JAMA Psychiatry 2014, 71:989-996.
44. Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton R Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. Arch Gen Psychiatry 2003, 60:709-717.
45. Kuloglu M, Atmaca M, Tezcan E, Ustundag B, Bulut S Antioxidant enzyme and malondialdehyde levels in patients with panic disorder. Neuropsychobiology 2002, 46:186-189.
46. Bouayed J, Rammal H, Soulimani R Oxidative stress and anxiety: relationship and cellular pathways. Oxid Med Cell Longev 2009, 2:63-67.
47. Dean O, Giorlando F, Berk M N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011, 36:78-86.
48. Helzer JE, Kraemer HC, Krueger RF The feasibility and need for dimensional psychiatric diagnoses. Psychol Med 2006, 36:1671-1680.
49. McGorry PD Risk syndromes, clinical staging and DSM V: new diagnostic infrastructure for early intervention in psychiatry. Schizophr Res 2010, 120:49-53.
50. Shankman SA, Lewinsohn PM, Klein DN, Small JW, Seeley JR, Altman SE Subthreshold conditions as precursors for full syndrome disorders: a 15-year longitudinal study of multiple diagnostic classes. J Child Psychol Psychiatry 2009, 50:1485-1494.
51. Karsten J, Hartman CA, Ormel J, Nolen WA, Penninx BWJH Subthreshold depression based on functional impairment better defined by symptom severity than by number of DSM-IV symptoms. J Affect Disord 2010, 123:230-237.
52. Hyman SE The diagnosis of mental disorders: the problem of reification. Annu Rev Clin Psychol 2010, 6:155-179.
53. Kendler KS, Zachar P, Craver C What kinds of things are psychiatric disorders?. Psychol Med 2011, 41:1143-1150.
54. Cuthbert BN, Insel TR Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project. Schizophr Bull 2010, 36:1061-1062.
55. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010, 167:748-751.
56. Millan MJ, Agid Y, Brüne M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 2012, 11:141-168.
57. De Raedt R, Koster EHW Understanding vulnerability for depression from a cognitive neuroscience perspective: a reappraisal of attentional factors and a new conceptual framework. Cogn Affect Behav Neurosci 2010, 10:50-70.
58. Peckham AD, McHugh RK, Otto MW A meta-analysis of the magnitude of biased attention in depression. Depress Anxiety 2010, 27:1135-1142.
59. Everaert J, Duyck W, Koster EH Attention, interpretation, and memory biases in subclinical depression: a proof-of-principle test of the combined cognitive biases hypothesis. Emotion 2014, 14:331-340.
60. Bar-Haim Y, Lamy D, Pergamin L, Bakermans-Kranenburg MJ, van IJzendoorn MH Threat-related attentional bias in anxious and nonanxious individuals: a meta-analytic study. Psychol Bull 2007, 133:1-24.
61. Cisler JM, Koster EHW Mechanisms of attentional biases towards threat in anxiety disorders: an integrative review. Clin Psychol Rev 2010, 30:203-216.
62. Sharbanee JM, Stritzke WG, Wiers RW, MacLeod C Alcohol-related biases in selective attention and action tendency make distinct contributions to dysregulated drinking behaviour. Addiction 2013, 108:1758-1766.
63. Bentall RP, Corcoran R, Howard R, Blackwood N, Kinderman P Persecutory delusions: a review and theoretical integration. Clin Psychol Rev 2001, 21:1143-1192.
64. Warman DM, Martin JM Cognitive insight and delusion proneness: an investigation using the Beck Cognitive Insight Scale. Schizophr Res 2006, 84:297-304.
65. Nieman DH, Bour LJ, Linszen DH, et al. Neuropsychological and clinical correlates of antisaccade task performance in schizophrenia. Neurology 2000, 54:866-871.
66. Nieman D, Becker H, van de Fliert R, et al. Antisaccade task performance in patients at ultra high risk for developing psychosis. Schizophr Res 2007, 95:54-60.
67. Van der Gaag M, Nieman DH, Rietdijk J, et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 2012, 38:1180-1188.
68. Van der Gaag M, Nieman DH, Van den Berg D CBT for those at risk for a first episode psychosis: evidence-based psychotherapy for people with an at risk mental state 2013, Routledge, Oxford, UK.
69. Van Oosterhout B, Krabbendam L, de Boer K, et al. Metacognitive group training for schizophrenia spectrum patients with delusions: a randomized controlled trial. Psychol Med 2014, 44:3025-3035.
70. McGorry P, Keshavan M, Goldstone S, et al. Biomarkers and clinical staging in psychiatry. World Psychiatry 2014, 13:211-223.
71. Hickie IB, Scott EM, Hermens DF, et al. Applying clinical staging to young people who present for mental health care. Early Interv Psychiatry 2013, 7:31-43.
72. Kapczinski F, Dias VV, Kauer-Sant'Anna M, et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1366-1371.
73. Beekman AT, van Os J, van Marle HJ, van Harten PN Staging and profiling of psychiatric disorders. Tijdschr Psychiatr 2012, 54:915-920.
74. McGorry PD, Purcell R, Hickie IB, Yung AR, Pantelis C, Jackson HJ Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust 2007, 187:S40.
75. Scott J Bipolar disorder: from early identification to personalized treatment. Early Interv Psychiatry 2011, 5:89-90.
76. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70:107-120.
77. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M Prediabetes: a high-risk state for diabetes development. Lancet 2012, 379:2279-2290.
78. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129(suppl 2):S1-45. the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
79. Ruhrmann S, Schultze-Lutter F, Schmidt SJ, Kaiser N, Klosterkötter J Prediction and prevention of psychosis: current progress and future tasks. Eur Arch Psychiatry Clin Neurosci 2014, 264(suppl 1):S9-16.
80. Briggs A, Spencer M, Wang H, Mannino D, Sin DD Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Arch Intern Med 2008, 168:71-79.
81. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008, 70:510-514.
82. Nieman DH, Ruhrmann S, Dragt S, et al. Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables. Schizophr Bull 2014, 40:1482-1490.
83. Bodatsch M, Ruhrmann S, Wagner M, et al. Prediction of psychosis by mismatch negativity. Biol Psychiatry 2011, 69:959-966.
84. Perez VB, Woods SW, Roach BJ, et al. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol Psychiatry 2014, 75:459-469.
85. Van Tricht MJ, Ruhrmann S, Arns M, et al. Can quantitative EEG measures predict clinical outcome in subjects at clinical high risk for psychosis? A prospective multicenter study. Schizophr Res 2014, 153:42-47.
86. Zimmermann R, Gschwandtner U, Wilhelm FH, Pflueger MO, Riecher-Rössler A, Fuhr P EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis. Schizophr Res 2010, 123:208-216.
87. Koutsouleris N, Riecher-Rössler A, Meisenzahl EM, et al. Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. Schizophr Bull 2015, 41:471-482.
88. Riecher-Rössler A, Pflueger MO, Aston J, et al. Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry 2009, 66:1023-1030.
89. Broome MR, Woolley JB, Johns LC, et al. Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur Psychiatry 2005, 20:372-378.
90. Fusar-Poli P, Byrne M, Badger S, Valmaggia LR, McGuire PK Outreach and support in south London (OASIS), 2001-2011: ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis. Eur Psychiatry 2013, 28:315-326.
91. Nieman DH, Rike WH, Becker HE, et al. Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. Int Clin Psychopharmacol 2009, 24:223-228.
92. International clinical practice guidelines for early psychosis. Br J Psychiatry 2005, 187:S120-S124. International Early Psychosis Association Writing Group.
93. Heinssen RK, Insel TR Preventing the onset of psychosis: not quite there yet. Schizophr Bull 2015, 41:28-29.
94. McGorry PD, Nelson B, Phillips LJ, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry 2013, 74:349-356.
95. Hutton P, Taylor PJ Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol Med 2014, 44:449-468.
96. Preti A, Cella M Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res 2010, 123:30-36.
97. Marshall M, Lockwood A Early intervention for psychosis. Cochrane Database Syst Rev 2004, 4. CD004718.
98. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013, 346:f185.
99. Van der Gaag M, Smit F, Bechdolf A, et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 2013, 149:56-62.
100. Lip GY, Edwards SJ Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006, 118:321-333.
101. Ising HK, Smit F, Veling W, et al. Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial. Psychol Med 2015, 45:1435-1446.
102. Cornblatt B, Lencz T, Obuchowski M The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr Res 2002, 54:177-186.
103. Lin A, Wood SJ, Nelson B, Beavan A, McGorry P, Yung AR Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am J Psychiatry 2015, 172:249-258.
104. Carrión RE, McLaughlin D, Goldberg TE, et al. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry 2013, 70:1133-1142.
105. Nelson B, Yuen HP, Wood SJ, et al. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study. JAMA Psychiatry 2013, 70:793-802.
106. McFarlane WR, Levin B, Travis L, et al. Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. Schizophr Bull 2015, 41:30-43.
107. McFarlane WR, Susser E, McCleary R, et al. Reduction in incidence of hospitalizations for psychotic episodes through early identification and intervention. Psychiatr Serv 2014, 65:1194-1200.
108. Yang LH, Wonpat-Borja AJ, Opler MG, Corcoran CM Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. Schizophr Res 2010, 120:42-48.
109. Warner R The prevention of schizophrenia: what interventions are safe and effective?. Schizophr Bull 2001, 27:551-562.
110. Morrison AP, Birchwood M, Pyle M, et al. Impact of cognitive therapy on internalised stigma in people with at-risk mental states. Br J Psychiatry 2013, 203:140-145.
111. Rüsch N, Müller M, Heekeren K, et al. Longitudinal course of self-labeling, stigma stress and well-being among young people at risk of psychosis. Schizophr Res 2014, 158:82-84.
112. Rüsch N, Corrigan PW, Heekeren K, et al. Well-being among persons at risk of psychosis: the role of self-labeling, shame, and stigma stress. Psychiatr Serv 2014, 65:483-489.
113. McGorry PD, Goldstone SD, Parker AG, Rickwood DJ, Hickie IB Cultures for mental health care of young people: an Australian blueprint for reform. Lancet Psychiatry 2014, 1:559-568.
114. McGorry PD, Tanti C, Stokes R, et al. Headspace: Australia's National Youth Mental Health Foundation-where young minds come first. Med J Aust 2007, 187(suppl):S68-S70.
115. Cross SP, Hermens DF, Scott EM, Ottavio A, McGorry PD, Hickie IB A clinical staging model for early intervention youth mental health services. Psychiatr Serv 2014, 65:939-943.
116. Rickwood DJ, Telford NR, Parker AG, Tanti CJ, McGorry PD Headspace-Australia's innovation in youth mental health: who are the clients and why are they presenting?. Med J Aust 2014, 200:108-111.
117. Muir K, Powell A, Patulny R, et al. Independent evaluation of headspace: the National Youth Mental Health Foundation 2009, Social Policy Research Centre, University of New South Wales, Sydney.
118. McGorry P, Bates T, Birchwood M Designing youth mental health services for the 21st century: examples from Australia, Ireland and the UK. Br J Psychiatry Suppl 2013, 54:s30-s35.